PG2
- Generic Name
- PG2
Astragalus Polysaccharides Alleviate Chemotherapy-Induced Fatigue in Breast Cancer Patients
• A double-blind, randomized, placebo-controlled trial investigated Astragalus polysaccharides (PG2) for chemotherapy-induced fatigue (CIF) in early breast cancer (EBC) patients.
• The study found that PG2 significantly reduced fatigue severity and improved overall quality of life compared to placebo during adjuvant chemotherapy.
• PG2, derived from Astragalus membranaceus, was administered intravenously alongside EC chemotherapy, showing a safe and effective profile for CIF relief.
• These findings suggest PG2 as a promising complementary therapy to mitigate fatigue and enhance HRQL in breast cancer patients undergoing chemotherapy.
PG2® Plus Chemoradiotherapy Improves Survival in Esophageal Cancer Patients
• A clinical study by PhytoHealth Corporation shows that Astragalus Polysaccharides (PG2®) combined with chemoradiotherapy (CCRT) significantly improves survival in advanced esophageal cancer patients.
• Patients receiving PG2® with CCRT had longer overall survival and a higher tumor objective response rate compared to those receiving CCRT alone, indicating enhanced treatment efficacy.
• PG2® modulates the tumor immune microenvironment (TIME), strengthens the immune system, and suppresses tumor growth, offering a new approach to esophageal cancer treatment.
• The study suggests PG2® can help patients complete cancer treatment by reducing inflammation, improving strength, and mitigating cancer-related fatigue, leading to better therapeutic outcomes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath